Entrada Therapeutics (TRDA) EBIT (2020 - 2026)

Entrada Therapeutics' EBIT history runs 7 years deep, the most recent figure standing at -$42.3 million for Q1 2026.

• In Q1 2026, EBIT fell 94.14% year-over-year to -$42.3 million; the TTM figure through Mar 2026 stood at -$178.4 million (down 4443.01% YoY), while the FY2025 annual figure was -$157.9 million, down 435.87% from the prior year.
• EBIT was -$42.3 million for Q1 2026 at Entrada Therapeutics, roughly flat from -$42.2 million in the prior quarter.
• In the past five years, EBIT ranged from a high of $53.4 million in Q2 2024 to a low of -$47.1 million in Q3 2025.
• Historically, EBIT has averaged -$14.9 million across 5 years, with a median of -$21.8 million in 2025.
• The sharpest annual moves came in 2024 and 2025: EBIT surged 465.28% in 2024, then sank 619.41% in 2025.
• A 5-year view of EBIT shows it stood at -$25.6 million in 2022, then surged by 119.18% to $4.9 million in 2023, then plunged by 219.61% to -$5.9 million in 2024, then tumbled by 619.41% to -$42.2 million in 2025, then fell by 0.23% to -$42.3 million in 2026.
• The last three EBIT figures came in at -$42.3 million (Q1 2026), -$42.2 million (Q4 2025), and -$47.1 million (Q3 2025), per Business Quant data.